New Oncology Clinical Trial Advancements Following ASCO 2024 

June 13, 2024

At the start of June, The American Society of Clinical Oncology (ASCO) held their annual meeting where experts gather to present their recent cancer research and results. The theme of this years ASCO was ‘The Art and Science of Cancer: From comfort to cure’ which influenced presentations to focus on the best therapeutic combinations to optimize quality of life during treatment for patients.  

An area that was particularly noteworthy was developments in cancer vaccines.  Merk’s collaboration with Moderna leverages mRNA technology to keep the immune system primed to destroy recurring cancer cells in melanoma patients. In trial, the vaccine showed improvement in 90% of patients. Elicio Therapeutics displayed their seven-peptide formula of its off-the-shelf vaccine ELI-002 7P. In phase 1 of their study, 71% of patients showed tumor biomarker reductions. 

Smaller young biotech companies also showed off results that seem promising for patients. In a phase 2 trial, Swedish biopharma Alligator Bioscience showed an increase in median overall survival with its antibody mitazalimab when compared to chemotherapy alone. The drug contains a unique combination of CD40 epitope and Fc receptor binding to provide strong effects. Nanobiotix, a French biotech, introduced new drug data for NBTXR3 this year. Containing electron-dense hafnium oxide nanoparticles, the drug is a one time injectable activated by radiotherapy. In patients with solid tumors who hadn’t yet received any treatment, 48% showed positive response to the drug. 

ASCO 2024 highlighted the remarkable progress being made in oncology clinical trials bringing hope to millions of patients worldwide. These advancements are paving the way for more effective and tailored cancer treatments. As these innovative approaches continue to evolve, they hold the promise of transforming cancer care and improving outcomes for patients across the globe. 

Related Articles

Biopharma Due for Rebound

Biopharma Due for Rebound

The biopharmaceutical industry is showing increased optimism for growth over the next 12 months, according to...